Effect of VDRA on survival in incident hemodialysis patients: Results of the FARO-2 observational study

Piergiorgio Messa, Mario Cozzolino, Diego Brancaccio, Giuseppe Cannella, Fabio Malberti, Anna Maria Costanzo, Umberto Di Luzio Paparatti, Vincenzo Festa, Giuliana Gualberti, Sandro Mazzaferro

Research output: Contribution to journalArticlepeer-review


Background: Mortality rate among patients with stage five chronic kidney disease (CKD) maintained on hemodialysis (HD) is high. Although evidence suggests that use of Vitamin D Receptor Activators (VDRA) in CKD patients increases survival, few studies have examined the effect of VDRA in incident HD patients. The FARO-2 study evaluated the clinical outcome of VDRA therapy on mortality in incident HD patients. Methods: FARO-2 was a longitudinal epidemiological study performed on 568 incident HD patients followed prospectively from 26 dialysis centers over a 3-year period. Data were collected every 6 months using a questionnaire, obtaining clinical, biochemical and therapeutic parameters. Kaplan-Meier curves and Cox proportional hazard regression models were used to determine cumulative probability of time-to-death and adjusted hazard ratios. Results: 568 patients (68% male) with an average age of 65.5 years were followed up. Mean dialysis duration at study entry was 3 months. VDRA use increased from 46% at 6 months to 54.7% at 36 months of follow-up (p = 0.08). No difference was observed in the presence of comorbid diseases at baseline in patients with and without VDRA therapy. Cumulative probability of survival at 24 months was 74.5% (95% CI: 70.2-78.3). Patients receiving VDRA therapy showed a significant increase in survival at 24 months (80.7%; 95% CI: 75.7-84.8) compared to those without (63.3%; 95% CI: 54.8-70.7, p

Original languageEnglish
Article number11
JournalBMC Nephrology
Issue number1
Publication statusPublished - Dec 1 2015


  • Calcitriol
  • Hemodialysis
  • Paricalcitol
  • PTH

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'Effect of VDRA on survival in incident hemodialysis patients: Results of the FARO-2 observational study'. Together they form a unique fingerprint.

Cite this